Cyclerion Therapeutics harnesses the potential of soluble guanylate cyclase (sGC) pharmacology.
Cyclerion Therapeutics has raised $5.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in May 2023.
Cyclerion Therapeutics's investors include Polaris Partners, Invus, EcoR1 Capital, Pappas Capital, Slate Path Capital.
Cyclerion Therapeutics is headquartered in Cambridge, United States.
Cyclerion Therapeutics harnesses the potential of soluble guanylate cyclase (sGC) pharmacology.
Cyclerion Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cyclerion Therapeutics — Funding & Investors." VCBacked, May 25, 2023, https://www.vcbacked.co/company/cyclerion-therapeutics. Accessed August 14, 2026.
VCBacked. (2023). Cyclerion Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/cyclerion-therapeutics
{{cite web |title=Cyclerion Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/cyclerion-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated